Gene study aims to predict breast cancer drug reactions
NCT ID NCT00896376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined blood samples from 49 women with metastatic breast cancer to find genetic markers that predict side effects from trastuzumab (Herceptin). The goal was to understand why some patients experience heart or allergic reactions. It did not test a new treatment, but aimed to improve future care by identifying who might be at higher risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can a new drug outsmart resistant breast cancer?